Toronto Dominion Bank Increases Holdings in Denali Therapeutics Inc. (NASDAQ:DNLI)

Toronto Dominion Bank lifted its position in Denali Therapeutics Inc. (NASDAQ:DNLI – Get Rating) by 2,132,400.0% in the third quarter, according to its most recent Form 13F filing with the SEC. The firm owned 42,650 shares of the company’s stock after purchasing an additional 42,648 shares during the period. Toronto Dominion Bank’s holdings in Denali Therapeutics were worth $1,308,000 at the end of the most recent quarter.

A number of other large investors have also recently modified their holdings of the company. China Universal Asset Management Co. Ltd. bought a new position in Denali Therapeutics in the third quarter worth approximately $35,000. Allspring Global Investments Holdings LLC raised its stake in Denali Therapeutics by 43.5% in the third quarter. Allspring Global Investments Holdings LLC now owns 3,313 shares of the company’s stock worth $101,000 after buying an additional 1,005 shares in the last quarter. Quantbot Technologies LP raised its stake in Denali Therapeutics by 362.5% in the third quarter. Quantbot Technologies LP now owns 3,700 shares of the company’s stock worth $113,000 after buying an additional 2,900 shares in the last quarter. Virtus ETF Advisers LLC raised its stake in Denali Therapeutics by 41.0% in the second quarter. Virtus ETF Advisers LLC now owns 4,839 shares of the company’s stock worth $142,000 after buying an additional 1,406 shares in the last quarter. Finally, Great West Life Assurance Co. Can bought a new position in Denali Therapeutics in the third quarter worth approximately $142,000. Hedge funds and other institutional investors own 67.26% of the company’s stock.

Get Denali Therapeutics alerts:

Denali Therapeutics Price Performance

Shares of DNLI opened at $29.92 on Wednesday. The firm has a market capitalization of $4.06 billion, a PE ratio of -12.11 and a beta of 1.37. Denali Therapeutics Inc. has a 1-year low of $20.24 and a 1-year high of $39.43. The company’s fifty day moving average price is $29.35 and its 200-day moving average price is $30.30.

Insider Activity

In other Denali Therapeutics news, Director Steve E. Krognes sold 1,377 shares of the company’s stock in a transaction on Wednesday, February 8th. The shares were sold at an average price of $30.88, for a total value of $42,521.76. Following the sale, the director now directly owns 145,121 shares of the company’s stock, valued at $4,481,336.48. The transaction was disclosed in a filing with the SEC, which is available through the SEC website. In other Denali Therapeutics news, Director Steve E. Krognes sold 1,377 shares of the company’s stock in a transaction on Wednesday, February 8th. The shares were sold at an average price of $30.88, for a total value of $42,521.76. Following the sale, the director now directly owns 145,121 shares of the company’s stock, valued at $4,481,336.48. The transaction was disclosed in a filing with the SEC, which is available through the SEC website. Also, CEO Ryan J. Watts sold 25,000 shares of the company’s stock in a transaction on Friday, February 10th. The shares were sold at an average price of $29.10, for a total transaction of $727,500.00. Following the completion of the sale, the chief executive officer now directly owns 2,229,031 shares in the company, valued at $64,864,802.10. The disclosure for this sale can be found here. Insiders have sold 75,086 shares of company stock valued at $2,218,638 over the last ninety days. 12.70% of the stock is currently owned by insiders.

Analysts Set New Price Targets

A number of equities analysts recently commented on the stock. Morgan Stanley boosted their price objective on shares of Denali Therapeutics from $60.00 to $65.00 and gave the stock an “overweight” rating in a research note on Wednesday, January 25th. Cowen started coverage on Denali Therapeutics in a research report on Monday, December 5th. They set an “outperform” rating on the stock. Cowen started coverage on Denali Therapeutics in a research report on Monday, December 5th. They set an “outperform” rating on the stock. Bank of America started coverage on Denali Therapeutics in a research report on Wednesday, November 2nd. They set a “buy” rating and a $40.00 price target on the stock. Finally, BTIG Research raised Denali Therapeutics from a “neutral” rating to a “buy” rating and set a $38.00 price target on the stock in a research report on Wednesday, November 2nd. Ten research analysts have rated the stock with a buy rating, According to MarketBeat.com, the company currently has a consensus rating of “Buy” and a consensus price target of $51.50.

Denali Therapeutics Profile

(Get Rating)

Denali Therapeutics, Inc is a biopharmaceutical company, which engages in the development and commercialization of a portfolio of product candidates for neurodegenerative diseases. Its product pipeline includes LRRK2, RIPK1, TREM2, and Tau. The company was founded by Ryan J. Watts, Marc Tessier-Lavigne, and Alexander Schuth on October 14, 2013 and is headquartered in San Francisco, CA.

Read More

• Get a free copy of the StockNews.com research report on Denali Therapeutics (DNLI)
• LCI Industries Diversification Strategy Pays Off
• Is It Time To Buy The Dip In The Coca-Cola Company 
• Ex-Dividend Date vs. Record Date: What’s the Difference?
• How Does the Consumer Price Index Affect the Stock Market?
• Are Denny’s Corporation Investors Due For A Grand Slam?

Want to see what other hedge funds are holding DNLI? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Denali Therapeutics Inc. (NASDAQ:DNLI – Get Rating).

Receive News & Ratings for Denali Therapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Denali Therapeutics and related companies with MarketBeat.com's FREE daily email newsletter.